BDX has filed for CE Mark approval for its Liverty TIPS Stent Graft, a next-generation device aimed at improving treatment for portal hypertension. CE Mark clearance would enable broader European commercialization and modestly expand BDX's vascular intervention footprint, representing a near-term product-catalyst contingent on regulatory outcome.
BDX has filed for CE Mark approval for its Liverty TIPS Stent Graft, a next-generation device aimed at improving treatment for portal hypertension. CE Mark clearance would enable broader European commercialization and modestly expand BDX's vascular intervention footprint, representing a near-term product-catalyst contingent on regulatory outcome.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
